Systemic Vasculitides: Current Status and Perspectives 1st ed. 2016 Edition
[amazon_link asins=’3319401343′ template=’ProductAd’ store=’aishabano-20′ marketplace=’US’ link_id=’2d753b19-4fe6-11e8-96e3-3f32b0c3786b’]
The systemic vasculitides,includinglarge, medium, small, and variable vessel vasculitis,have been the focus of intensive basic and clinical investigations over the last twodecades. Among theimportant advances stemming from these efforts are new definitions, classifications, and diagnostic criteria for the different classes of vasculitis; the addition of anti-neutrophil cytoplasmic autoantibodies as a new criterion for classifying vasculitis; the recognition of the viral etiology of conditions such as cryoglobulinemic vasculitis and polyarteritis nodosa; an appreciation of thebroad spectrum of clinical manifestations and potentially devastating complicationsassociated with vasculitis; the many features and remarkable clinical heterogeneity of IgG4-related, immune-mediated diseases; and the proposal of intriguing pathogenetic hypotheses for certain chronic, relapsing vasculitides.
This improved understanding of the systemic vasculitides has been accompanied by a trend away from the use of eponyms for these conditions; thus, established terms such as Wegener’s granulomatosis and Churg-Strauss syndrome have been replacedby the more descriptive definitions “granulomatosis with polyangiitis” and “eosinophilic granulomatosis with polyangiitis,” respectively.
Additional clinical laboratory tests,rapidly developing imaging techniques that can assess inflammation, especially in large-vessel vasculitis, and artificial neural network approaches will no doubt bring a wealth of informationthat ultimately leads to the identification of novel disease biomarkers. Expected applications include the identification of individuals at increased risk ofrelapsewho would benefit from patient-tailored therapy. Although the conventional combination of glucocorticoids and immunosuppressive drugs is effective in the treatment of a large proportion of vasculitic disorders, safer medications, with fewer side effects, are being developed, includingseveral biological agents now being closely evaluated in multi-center studies.
DOWNLOAD THIS BOOK FREE HERE
This website strictly complies with DMCA Digital Copyright Laws..Please be clear that we (emedicalbooks.com) do not own copyrights of these e-books. The intention behind sharing these books and educational material is to provide easy access to medical students, doctors and other individuals related to the field of medical science, "thus only for educational purpose". We highly encourage our readers to purchase this content from the respected publishers. If anyone holding copyrights wants us to remove this content, please contact us rightaway. All books and educational material on emedicalbooks.com are free and NOT HOSTED ON OUR WEBSITE. If you feel that your copyrights have been violated, then please contact us immediately. You may send an email to firstname.lastname@example.org for all DMCA / Removal Requests. emedicalbooks.com doesn’t have any material hosted on the server of this page, only links to books that are taken from other sites on the web are published and these links are unrelated to the book server. emedicalbooks.com server doesnot store any type of book or material. No illegal copies are made or any copyright © and / or copyright is damaged or infringed since all material is free on the internet.